Insider Selling: Tempus AI (NASDAQ:TEM) Director Sells $12,350.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 250 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $49.40, for a total transaction of $12,350.00. Following the transaction, the director directly owned 31,464 shares in the company, valued at approximately $1,554,321.60. This represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

NASDAQ:TEM opened at $46.43 on Friday. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32. The firm has a market cap of $8.34 billion, a price-to-earnings ratio of -26.99 and a beta of 3.62. The firm’s 50-day simple moving average is $48.89 and its 200 day simple moving average is $57.48. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period last year, the firm earned ($0.24) earnings per share. Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. As a group, sell-side analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently bought and sold shares of TEM. Royal Bank of Canada boosted its stake in shares of Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after purchasing an additional 17,359 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Tempus AI in the 1st quarter valued at approximately $116,000. Prudential Financial Inc. acquired a new stake in shares of Tempus AI in the 2nd quarter valued at approximately $276,000. Russell Investments Group Ltd. boosted its stake in shares of Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Tempus AI by 2,926.6% in the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock valued at $13,446,000 after purchasing an additional 204,629 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on TEM. Morgan Stanley lowered their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Robert W. Baird started coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a report on Monday, June 1st. Guggenheim decreased their target price on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Finally, Stifel Nicolaus set a $60.00 target price on shares of Tempus AI in a report on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.